Literature DB >> 20684954

Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis.

Daniel Bodri1, Sesh Kamal Sunkara, Arri Coomarasamy.   

Abstract

OBJECTIVE: To compare GnRH agonists and antagonists in oocyte-donation IVF treatment cycles by a systematic review and meta-analysis of trials.
DESIGN: Systematic review and meta-analysis of randomized clinical trials (RCT). Systematic literature searches were conducted, and all randomized trials that compared GnRH agonists with antagonists in oocyte-donation IVF treatment cycles were included. Study selection, quality appraisal, and data extractions were performed independently and in duplicate.
SETTING: Tertiary fertility center. PATIENT(S): A total of 1,024 oocyte donors treated in eight RCTs. INTERVENTION(S): Comparison of GnRH agonists versus antagonists in oocyte-donation IVF treatment. MAIN OUTCOME MEASURE(S): Ongoing pregnancy, oocytes retrieved, duration of stimulation, gonadotropin consumption, and ovarian hyperstimulation syndrome incidence (OHSS) per randomized oocyte donor. RESULT(S): Meta-analysis of these studies showed no significant difference in ongoing pregnancy rate between the GnRH agonists and antagonists (risk ratio [RR] 1.15, 95% confidence interval [CI] 0.97 to 1.36). The duration of stimulation was significantly lower with the GnRH antagonist protocol (weighed mean difference [WMD] -0.90 days, 95% CI -1.61 to -0.20). No significant differences were observed in the number of oocytes retrieved (WMD -0.60, 95% CI -2.26 to +1.07), gonadotropin consumption (WMD -264 IU, 95% CI -682 to +154), or OHSS incidence (RR 0.62, 95% CI 0.18 to 2.15). CONCLUSION(S): No significant differences were observed in ongoing pregnancy rate or the number of retrieved oocytes after donor stimulation with GnRH agonist or antagonist protocols.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20684954     DOI: 10.1016/j.fertnstert.2010.06.068

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  19 in total

1.  Different ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience.

Authors:  Massimo Manno; Marta Cervi; Donatella Zadro; Giuseppa Fuggetta; Valter Adamo; Francesco Tomei
Journal:  J Assist Reprod Genet       Date:  2011-04-26       Impact factor: 3.412

2.  Effect of lower than expected number of oocyte on the IVF results after oocyte-pickup.

Authors:  Süheyla Gonca; Ismet Gün; Ali Ovayolu; Dilek Silfeler; Kenan Sofuoğlu; Ozkan Ozdamar; Ali Yilmaz; Gülden Tunali
Journal:  Int J Clin Exp Med       Date:  2014-07-15

3.  Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.

Authors:  Qiaohong Lai; Hanwang Zhang; Guijing Zhu; Yufeng Li; Lei Jin; Long He; Zhijun Zhang; Ping Yang; Qilin Yu; Shu Zhang; Jun-Fa Xu; Cong-Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

4.  Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders.

Authors:  Min Xia; Jie Zheng
Journal:  BMC Pregnancy Childbirth       Date:  2021-05-11       Impact factor: 3.007

Review 5.  GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).

Authors:  Raffaella Depalo; K Jayakrishan; Gabriella Garruti; Ilaria Totaro; Mariantonietta Panzarino; Francesco Giorgino; Luigi E Selvaggi
Journal:  Reprod Biol Endocrinol       Date:  2012-04-13       Impact factor: 5.211

6.  Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?

Authors:  Yaakov Bentov; Eliezer Burstein; Courtney Firestone; Ross Firestone; Navid Esfandiari; Robert F Casper
Journal:  Reprod Biol Endocrinol       Date:  2013-02-22       Impact factor: 5.211

7.  GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology.

Authors:  Ana Marcia M Cota; Joao Batista A Oliveira; Claudia G Petersen; Ana L Mauri; Fabiana C Massaro; Liliane F I Silva; Andreia Nicoletti; Mario Cavagna; Ricardo L R Baruffi; José G Franco
Journal:  Reprod Biol Endocrinol       Date:  2012-04-27       Impact factor: 5.211

8.  Pregnancy rates with recombinant versus urinary human chorionic gonadotropin in in vitro fertilization: an observational study.

Authors:  József Zeke; Katalin Kanyó; Helga Zeke; Aron Cseh; Barna Vásárhelyi; András Szilágyi; János Konc
Journal:  ScientificWorldJournal       Date:  2011-10-19

9.  Using a mild stimulation protocol combined with clomiphene citrate and recombinant follicle-stimulating hormone to determine the optimal number of oocytes needed to achieve pregnancy and reduce the concerns of patients.

Authors:  Rikikazu Sugiyama; Koji Nakagawa; Yayoi Nishi; Yuko Ojiro; Hiroyasu Juen; Rie Sugiyama; Yasushi Kuribayashi
Journal:  Reprod Med Biol       Date:  2013-04-17

Review 10.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.